Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eIF4E inhibitor

- PMLiVE

Pfizer confirms interest in AstraZeneca megamerger

Says it has twice tried to engage in merger talks with big pharma rival

- PMLiVE

Pfizer set to file Xeljanz for psoriasis

Set to add another indication after positive study results

- PMLiVE

Pfizer rumoured to be after AstraZeneca

Is this the return of the pharma mega-merger?

- PMLiVE

Pfizer’s Emms takes up ABPI presidency

He succeeds MSD’s Deepak Khanna at the UK pharma industry body

- PMLiVE

Pfizer’s breast cancer drug palbociclib extends survival

Positive trial results for oncology treatment

- PMLiVE

Pfizer appoints comms head in Spain

Monica Piñuela is promoted

- PMLiVE

Merck KGaA and Pfizer collaborate on lupus

Companies team up with academics to research treatments for autoimmune disorder

- PMLiVE

Pfizer gains ground in cholesterol antibody chase

 Reports positive phase 2b data for its PCSK9 blocker

- PMLiVE

Pfizer says Xalkori tops chemo as first line therapy

Superior progression free survival for lung cancer patients

- PMLiVE

Pfizer’s meningitis vaccine ‘a breakthrough’

FDA to speed up review process for bivalent rLP2086

- PMLiVE

FDA approves new indication for Pfizer/BMS’ Eliquis

Oral anticoagulant gains US approval for deep vein thrombosis use

- PMLiVE

Pfizer 2014 guidance threatened by Celebrex competition

Court overturns key patent for osteoarthritis drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links